This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Galapagos Nv. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: Marcel Hoffmann: Innovator in Alzheimer's Research
Introduction
Marcel Hoffmann is a notable inventor based in Uithoorn, Netherlands. He has made significant contributions to the field of biomedical research, particularly in the area of Alzheimer's disease. His innovative work focuses on methods to identify compounds that can inhibit the production of amyloid-beta protein, which is crucial in the development of cognitive impairments.
Latest Patents
Hoffmann holds a patent for "Methods for identifying a compound that inhibits the procession of amyloid-beta protein production in a mammalian cell expressing APP and overexpressing a G-protein coupled receptor in the cell." This method involves contacting a test compound with a GPCR polypeptide and measuring a compound-GPCR property related to the production of amyloid-beta peptide. The cellular assays associated with this method measure indicators such as second messenger levels and amyloid-beta peptide levels. His therapeutic methods and pharmaceutical compositions are aimed at treating conditions involving cognitive impairment, including Alzheimer's disease.
Career Highlights
Marcel Hoffmann is associated with Galapagos NV, a company known for its innovative approaches in drug discovery and development. His work at Galapagos has positioned him as a key player in the fight against neurodegenerative diseases.
Collaborations
Hoffmann has collaborated with notable colleagues, including Koenraad Frederik Florentina Spittaels and Pascal Gerard Merchiers. These collaborations have further enhanced his research and development efforts in the field.
Conclusion
Marcel Hoffmann's contributions to Alzheimer's research through his innovative patent and work at Galapagos NV highlight his commitment to advancing medical science. His efforts are paving the way for potential therapeutic solutions for cognitive impairments.